Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy...
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the...
U.S. Government Issues Request for Proposal for the Supply of 44.75 Million Doses of BioThrax over Next 5 Years
Emergent BioSolutions Inc. Investors Contact: Robert G. Burrows Vice President, Investor Relations 301-795-1877 BurrowsR@ebsi.com or Media Contact: Tracey Schmitt Vice President, Corporate...
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2011 at 10:00 am Eastern; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2011 beginning at 10:00 am Eastern Time at the Sheraton Rockville...
Emergent BioSolutions Reports Financial Results for First Quarter 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the first quarter ended March 31,...
U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million
mergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a modification to its current procurement contract (200-2009-30162) with the U.S. government to supply an additional 3.42...
Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium (OETC), has vaccinated the last of the...
Emergent BioSolutions to Release First Quarter 2011 Financial Results and Conduct a Conference Call on May 5, 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the first quarter 2011 on Thursday, May 5, 2011, after market...
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry...
Emergent BioSolutions Observes World TB Day
Emergent BioSolutions Inc. (NYSE:EBS) today released the following statement in observance of World TB...
Emergent BioSolutions to Present at Needham & Company Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5,...